Medical
100 Most Popular
Most Popular Under $25

Teva Pharmaceutical

$16.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.75 (-4.39%) Today
-$0.04 (-0.24%) After Hours

Why Robinhood?

You can buy or sell TEVA and other stocks, options, ETFs, and crypto commission-free!

About

Teva Pharmaceutical Industries Limited American Depositary Shares, also called Teva Pharmaceutical, is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines. Read More The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Employees
42,535
Headquarters
Petach Tikva, HaMerkaz
Founded
1901
Market Cap
17.80B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
11.18M
High Today
$17.00
Low Today
$16.33
Open Price
$16.96
Volume
6.47M
52 Week High
$25.96
52 Week Low
$14.59

Collections

Medical
100 Most Popular
Most Popular Under $25
Healthcare
Pharmaceutical
Health
Manufacturing
Chemicals

News

Seeking AlphaMar 22

Teva launches generic Exjade in U.S.

Teva Pharmaceutical Industries (NYSE:TEVA) announces the U.S. commercial launch of its generic version of Novartis' iron overload med Exjade (deferasirox).

230
MarketWatchMar 20

Teva Pharmaceutical Industries Ltd. ADR

Teva Pharmaceutical Industries Ltd. shares tumbled 11% in premarket trade Wednesday, after the Israeli generics company missed earnings estimates for the fourth quarter and offered guidance that was also below consensus. The company said it had a net loss of $2.940 billion, or $2.85 a share, in the quarter, narrower than the loss of $11.600 billion, or $11.41 a share, posted in the year-earlier period. Excluding impairment charges and restructuring costs, the company had adjusted per-share earnings of 53 ce...

652
Yahoo FinanceMar 18

Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $16.64, moving +0.79% from the previous trading session. This change outpaced the S&P 500's 0.37% gain on the day. Elsewhere, the Dow gained 0.25%, while the tech-heavy Nasdaq added 0.34%. Prior to today's trading, shares of the company had lost 4.46% over the past month. This has lagged the Medical sector's gain of 1.34% and the S&P 500's gain of 1.83% in that time. Wall Street will be looking for positivity from TEVA as it ...

704

Earnings

$0.53
$0.71
$0.90
$1.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.